Publications

Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model.
Mol Cancer Ther 2014 Apr 21;13(4):823-32. Epub 2014 Jan 21.
Authors' Affiliations: Eisai Co., Ltd.; and Genomics-Based Drug Discovery, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan.


OF